Search results for "Alanine"

showing 10 items of 499 documents

Reduced Cerebral Fluoro-l-Dopamine Uptake in Adult Patients Suffering from Phenylketonuria

2007

Deficiency of phenylalanine hydroxylase activity in phenylketonuria (PKU) causes an excess of phenylalanine (Phe) throughout the body, predicting impaired synthesis of catecholamines in the brain. To test this hypothesis, we used positron emission tomography (PET) to measure the utilization of 6-[18F]fluoro-l-dopamine (FDOPA) in the brain of adult patients suffering from PKU and in healthy controls. Dynamic 2-h long FDOPA emission recordings were obtained in seven adult PKU patients (five females, two males; age: 21 to 27 years) with elevated serum Phe levels, but lacking neurologic deficits. Seven age-matched, healthy volunteers were imaged under identical conditions. The utilization of F…

AdultMaleFluorine Radioisotopesmedicine.medical_specialtyPhenylalanineCentral nervous system diseasechemistry.chemical_compoundDopaminePhenylketonuriasInternal medicinemedicineHumansNeurotransmitterAdult patientsmedicine.diagnostic_testbusiness.industrymedicine.diseaseCorpus StriatumDihydroxyphenylalanineEndocrinologyNeurologychemistryPositron emission tomographyPositron-Emission TomographyCatecholamineFemaleNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessPhenylalanine hydroxylase activitymedicine.drugJournal of Cerebral Blood Flow & Metabolism
researchProduct

Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

2013

Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with limited treatment efficacy. A study was undertaken to investigate whether treatment extension to 96 weeks improves the outcome in this patient population.128 HBeAg-negative patients (120 genotype D) were randomised to weekly 180 μg PegIFN for 48 weeks (group A, n=51), 180 μg PegIFN for 48 weeks followed by 135 μg weekly for an additional 48 weeks (group B, n=52) or 180 μg PegIFN plus lamivudine (100 mg/day) for 48 weeks then 135 μg PegIFN for 48 weeks (group C, n=25). Endpoints were alanine aminotransferase normalisa…

AdultMaleHBsAgmedicine.medical_specialtyHepatitis B virusTime FactorsAnti-HIV Agentsmedicine.disease_causeGastroenterologyAntiviral AgentsGroup Blaw.inventionPolyethylene GlycolsPharmacotherapyHepatitis B ChronicRandomized controlled triallawPegylated interferonInternal medicinemedicineHumansHepatitis B e AntigensHepatitis B virusbusiness.industryGastroenterologyLamivudineInterferon-alphaAlanine TransaminaseHepatitis BMiddle Agedmedicine.diseaseHepatitis BRecombinant ProteinsTreatment OutcomeLamivudineImmunologyDNA ViralInterferonDrug Therapy CombinationFemaleHepatitis B; Interferonbusinessmedicine.drug
researchProduct

Clinical evaluation and applications of the Amplicor HBV Monitor™ test, a quantitative HBV DNA PCR assay

1998

Viral load has emerged recently as a reliable marker of disease progression and therapeutic efficacy in chronic infections, including AIDS and hepatitis C. The clinical management of type B hepatitis could also be improved by monitoring viremia levels in patients with chronic liver disease undergoing anti-viral treatment. To address this question we evaluated the performance of a newly developed, quantitative PCR assay (Amplicor HBV Monitor test, Roche Diagnostic Systems) in the assessment of viremia changes over time in a group of 45 patients with chronic active hepatitis (CAH) who received interferon treatment. Of the 45 patients, 14 were HBsAg and anti-HBeAg positive and 31 HBsAg, HBeAg …

AdultMaleHepatitis B virusHBsAgImmunoblottingViremiaBiologymedicine.disease_causePolymerase Chain ReactionHepatitis B ChronicVirologymedicineHumansHepatitis B e AntigensViremiaHepatitis B AntibodiesHepatitisHepatitis B virusHepatitis B Surface AntigensInterferon-alphavirus diseasesAlanine TransaminaseMiddle AgedViral LoadHepatitis Bmedicine.diseasebiology.organism_classificationVirologydigestive system diseasesTreatment OutcomeImmunoglobulin MHBeAgHepadnaviridaeEvaluation Studies as TopicDNA ViralImmunologyFemaleViral loadJournal of Virological Methods
researchProduct

Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C

2003

Occult HBV infection in subjects with chronic hepatitis C is related to more severe disease outcome. It has been suggested that it might reduce sensitivity to antiviral treatment.To assess in HBsAg negative subjects with chronic hepatitis C any effect of the presence of HBV genomes in the liver on the early kinetics of HCV-RNA under PEG-IFN plus ribavirin.Twenty-two anti-HCV and HCV-RNA positive subjects, with biopsy-proven chronic hepatitis C (M/F 15/7; 50 +/- 8.6 years, 16 genotype 1b) were given PEG-IFN alpha 2b 1.0 microg qw plus ribavirin (800 to 1,200 mg daily according to body weight) for an intended 52 week period. Early virological response was assessed over the first 4 weeks of th…

AdultMaleHepatitis B viruspegylated interferon-alphaGenotypeBiopsyHepacivirusInterferon alpha-2Virus ReplicationAntiviral AgentsPolyethylene GlycolsHepatitis B AntibodieRibavirinchronic hepatitis CHumansHepatitis B AntibodiesAntiviral AgentHepaciviruoccult HBV infection; chronic hepatitis C; pegylated interferon-alpha; viral dynamics; treatment responseoccult HBV infectiontreatment responseInterferon-alphaAlanine TransaminaseHepatitis B viruHepatitis C AntibodiesHepatitis C ChronicMiddle AgedRecombinant ProteinViral LoadHepatitis Bviral dynamicsRecombinant ProteinsTreatment OutcomeLiverDNA ViralRNA ViralDrug Therapy CombinationFemaleHepatitis C AntibodieHuman
researchProduct

Circulating intercellular adhesion molecule-1 in chronic hepatitis C patients with normal or elevated aminotransferase before and after alpha-interfe…

2001

<i>Objectives:</i> Intercellular adhesion molecule-1 (ICAM-1) plays a fundamental role during liver inflammation. In fact, weak ICAM-1 expression is physiologically restricted to the endothelium of portal vessels and to sinusoidal lining cells, but it becomes markedly evident on sinusoidal lining cells and at the surface of hepatocytes during inflammatory liver diseases. The aim of this study was to evaluate the behaviour of soluble ICAM-1 (sICAM-1) in chronic hepatitis C (CH-C) patients with persistently normal aminotransferase in comparison with patients with CH-C and elevated aminotransferase, and its changes during α-interferon (IFN) therapy. Immunohistochemical localization…

AdultMaleIntercellular Adhesion Molecule-1Alpha interferonInflammationInterferon alpha-2BiologyChronic hepatitis CAntiviral Agentsα-InterferonLiver diseaseChronic hepatitisVirologymedicineHumansAspartate Aminotransferasesα interferonInterferon-alphaAlanine TransaminaseAdhesionIntercellular adhesion molecule-1Hepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsInfectious DiseasesImmunologyCancer researchFemalemedicine.symptomLiver diseaseIntracellular
researchProduct

Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin

2012

It is unclear whether the current threshold for 'high' hepatitis C virus (HCV) RNA level (800,000 IU/mL) is optimal for predicting sustained virological response (SVR). We retrospectively analysed pretreatment HCV RNA levels and SVR rates in 1529 mono-infected and 176 HIV-HCV co-infected patients treated with peginterferon alfa-2a (40 kD) plus ribavirin. We improved the threshold for differentiating low and high viral load by fitting semiparametric generalized additive logistic regression models to the data and constructing receiver operating characteristics curves. Among HCV genotype 1 mono-infected patients, the difference in SVR rates between those with low and high baseline HCV RNA leve…

AdultMaleInterferon-alphaAlanine TransaminaseHepacivirusMiddle AgedViral LoadAntiviral AgentsHepatitis CRecombinant ProteinsPolyethylene GlycolsLogistic ModelsTreatment OutcomeROC CurveRibavirinHumansRNA ViralDrug Therapy CombinationFemalehepatitis CRetrospective Studies
researchProduct

Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET

2009

Abstract Transcranial ultrasound (TCS) has been shown to reveal hyperechogenicity of the substantia nigra (SN) in Parkinsonian patients and in about 10% of healthy controls. It is hypothesized that SN hyperechogenicity in healthy subjects is a vulnerability marker for idiopathic Parkinson's disease (IPD). Although there is strong evidence that the echomarker results from increased local iron content, the exact pathophysiological mechanisms remain incompletely understood. Thus, prognostic impact can only be estimated. We examined 14 subjects with SN hyperechogenicity (SN+) (7 IPD patients and 7 controls) and 7 healthy controls without the echomarker (SN−) by a magnetic resonance imaging meth…

AdultMalePathologymedicine.medical_specialtyCognitive NeuroscienceSubstantia nigraReference ValuesmedicineHumansNeuronsmedicine.diagnostic_testbusiness.industryTissue inhomogeneityHealthy subjectsParkinson DiseaseMagnetic resonance imagingMiddle AgedEchoencephalographyMagnetic Resonance ImagingPathophysiologyDihydroxyphenylalanineTranscranial DopplerSubstantia NigraNeurologyPositron-Emission TomographyT2 relaxationIron contentFemaleRadiopharmaceuticalsbusinessNeuroImage
researchProduct

Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases.

2010

Abstract Background/Aim Plasma cells infiltrate in the liver is a prototype lesion of autoimmune liver diseases. The possible role of plasma cells isotyping (IgM and IgG) in the liver in the diagnostic definition of autoimmune liver disease, and particularly in variant syndromes such as autoimmune cholangitis and the primary biliary cirrhosis/autoimmune hepatitis overlap syndrome, is less defined. Methods We analysed the clinical, serological and histological features of 83 patients with autoimmune liver disease (40 primary biliary cirrhosis, 20 autoimmune hepatitis, 13 primary sclerosing cholangitis, 4 autoimmune cholangitis and 6 overlap syndrome) compared to 34 patients with chronic hepa…

AdultMalePathologymedicine.medical_specialtyLiver kidney microsomal type 1 antibodyCholangitisBiopsyCholangitis SclerosingPlasma CellsAutoimmune hepatitisAutoimmune cholangitis Autoimmune hepatitis IgG plasma cells IgM plasma cells Immunostaining Liver biopsy Overlap syndromes Portal infiltrate Primary biliary cirrhosisSettore MED/08 - Anatomia PatologicaAutoimmune DiseasesPrimary sclerosing cholangitisSex FactorsPrimary biliary cirrhosismedicineHumansAgedAutoantibodiesHepatitisSettore MED/12 - GastroenterologiaHepatologymedicine.diagnostic_testLiver Cirrhosis Biliarybusiness.industryGastroenterologyAlanine TransaminaseOverlap syndromegamma-GlutamyltransferaseMiddle AgedAlkaline Phosphatasemedicine.diseaseHepatitis CHepatitis AutoimmuneImmunoglobulin MLiverImmunoglobulin GLiver biopsyFemaleBile DuctsbusinessAnti-mitochondrial antibody
researchProduct

Everyday Life, Dietary Practices, and Health Conditions of Adult PKU Patients: A Multicenter, Cross-Sectional Study

2020

<b><i>Background:</i></b> Only few data on dietary management of adult phenylketonuria (PKU) patients are published. <b><i>Objectives:</i></b> This study aimed to assess living situation, dietary practices, and health conditions of early-treated adult PKU patients. <b><i>Methods:</i></b> A total of 183 early-treated PKU patients ≥18 years from 8 German metabolic centers received access to an online survey, containing 91 questions on sociodemographic data, dietary habits, and health conditions. <b><i>Results:</i></b> 144/183 patients (66% females) completed the questionnaire. Compared with German …

AdultMalePediatricsmedicine.medical_specialtyAdolescentCross-sectional studyHealth StatusPhenylalanineMedicine (miscellaneous)Living situationProfessional statusYoung AdultQuality of lifePhenylketonuriasSurveys and QuestionnairesActivities of Daily LivingDiet Protein-RestrictedPrevalenceHumansChildbirthMedicineAmino acid intakeAmino AcidsEveryday lifeNutrition and DieteticsDepressionbusiness.industryDietary managementFeeding BehaviorMiddle AgedCross-Sectional StudiesDietary SupplementsQuality of LifePatient ComplianceFemalebusinessAnnals of Nutrition and Metabolism
researchProduct

Analysis of genetic variations of protein tyrosine kinase fyn and their association with alcohol dependence in two independent cohorts.

2003

Abstract Background Decreased sensitivity to and increased tolerance for the effects of alcohol is a phenotype, which was shown to be associated with an increased risk for alcoholism in humans and was observed in protein tyrosine kinase (PTK) fyn knockout mice. Methods We performed an association study of genetic variations of PTK fyn in 430 alcohol-dependent patients and 365 unrelated control subjects from two independent samples. Results In a combined analysis, we found an association of alcohol dependence with the single nucleotide polymorphism (SNP) T137346C in the 5′ untranslated region (UTR) of the gene. A relevant association could be excluded for the remaining two informative SNPs. …

AdultMaleThreonineLinkage disequilibriumGenotypeGlycineSingle-nucleotide polymorphismBiologyProto-Oncogene Proteins c-fynPolymorphism Single NucleotideCohort StudiesFYNGene FrequencyProto-Oncogene ProteinsGenotypeSNPHumansCysteineAlleleBiological PsychiatryGeneticsAlanineChi-Square DistributionAlcohol dependenceGenetic VariationMiddle AgedAlcoholismCase-Control StudiesFemale5' Untranslated RegionsTyrosine kinaseBiological psychiatry
researchProduct